# Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

> **NCT03806049** · PHASE3 · WITHDRAWN · sponsor: **Nordic Society of Gynaecological Oncology - Clinical Trials Unit**

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Bevacizumab
- **DRUG:** TSR042
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03806049
- **Lead sponsor:** Nordic Society of Gynaecological Oncology - Clinical Trials Unit
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12
- **Primary completion:** 2022-12
- **Final completion:** 2024-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of financial support
- **Last updated:** 2021-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03806049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03806049, "Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT03806049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*